Academic Journal
Q1Nature Reviews Clinical Oncology
Q1Ranking
81.100Impact Factor
259H-index
28.076SJR
30.3Research Score
2009-2026Coverage
About Nature Reviews Clinical Oncology
Nature Reviews Clinical Oncology is a scholarly journal published by Nature Publishing Group. SCImago 2025 places it in Q1 with an SJR of 28.076 and an H-index of 259.
Its listed coverage is 2009-2026 and its research categories include Oncology (Q1). The 2025 dataset reports 126 documents and 14731 citations across the latest three-year reporting window.
1. Expert Reviews and Opinions
The journal features in-depth reviews written by renowned experts in oncology. These reviews provide a critical evaluation of recent research, helping clinicians and researchers stay informed about cutting-edge developments in cancer treatment and management.2. Latest Advances in Oncology
From targeted therapies to immunotherapy breakthroughs, Nature Reviews Clinical Oncology covers a wide range of innovative treatment strategies. The journal keeps its audience updated with the latest trends and discoveries shaping the future of cancer care.3. High-Impact Research Summaries
The journal summarizes key clinical trials, studies, and meta-analyses, making complex scientific findings accessible to a broader medical audience. This helps oncologists and healthcare professionals make evidence-based decisions in patient care.4. Multidisciplinary Approach
Cancer treatment requires a holistic approach, and the journal emphasizes collaboration across disciplines such as medical oncology, surgical oncology, radiation therapy, and palliative care. This multidisciplinary perspective ensures that various aspects of cancer management are addressed.Why is Nature Reviews Clinical Oncology Important?
1. Reliable Source of Oncology Updates
The journal is a trusted source of oncology research, offering insights that help healthcare professionals stay ahead in the field. With rapidly evolving cancer treatments, staying informed through reputable sources like Nature Reviews Clinical Oncology is crucial.2. Enhancing Clinical Practice
By presenting expert-reviewed insights, the journal helps oncologists refine their treatment approaches, ultimately improving patient outcomes. It serves as a bridge between research and clinical practice.3. Guiding Future Research
Many researchers use the journal as a reference for their studies, ensuring that future cancer research builds upon well-established knowledge and emerging discoveries.SEO Benefits of Reading Nature Reviews Clinical Oncology
For healthcare professionals and researchers looking to enhance their online presence, referencing reputable journals like Nature Reviews Clinical Oncology can boost credibility. Publishing content based on its findings improves SEO rankings by incorporating authoritative information and relevant keywords such as "oncology research," "cancer treatment breakthroughs," and "clinical oncology insights."Journal Metrics
RankingQ1
Impact Factor81.100
H-index259
SJR28.076
Research Score30.3
Coverage2009-2026
ISSN17594774, 17594782
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Nature Reviews Clinical Oncology is a highly respected peer-reviewed journal that provides in-depth reviews and expert opinions on critical developments in clinical oncology. As part of the prestigious Nature Reviews series, this journal offers insightful analysis on cancer research, treatment advancements, and emerging trends in oncology. It is a must-read for oncologists, researchers, and medical professionals aiming to stay updated with the latest breakthroughs in cancer care.
Scope and Coverage
The journal covers a broad spectrum of oncology-related topics, including but not limited to:- Molecular Oncology: Exploring the latest genetic and molecular insights into cancer pathogenesis.
- Cancer Treatment Innovations: Reviewing advancements in chemotherapy, immunotherapy, targeted therapy, and precision medicine.
- Clinical Trials and Research: Providing updates on groundbreaking clinical trials and their impact on treatment protocols.
- Surgical and Radiation Oncology: Discussing new techniques and approaches for more effective cancer treatment.
- Epidemiology and Prevention: Analyzing cancer risk factors, prevention strategies, and early detection methods.
Nature of Content
The content published in Nature Reviews Clinical Oncology is known for its authoritative and evidence-based approach. The journal features:- Comprehensive Reviews: Detailed analysis of recent studies, providing a synthesized perspective on complex oncology topics.
- Expert Opinions: Contributions from leading oncologists and researchers who share their insights on pressing challenges in cancer treatment.
- Clinical Implications: Practical applications of research findings for clinical practice, aiding healthcare professionals in making informed decisions.
- Cutting-Edge Research Summaries: Summarized findings from key clinical trials and laboratory research, keeping readers informed about recent advancements.
Impact and Readership
With a high impact factor and extensive readership, Nature Reviews Clinical Oncology plays a crucial role in shaping the future of cancer treatment. Its audience includes:- Oncologists and medical professionals seeking updated treatment guidelines.
- Researchers looking for comprehensive reviews of new studies and emerging trends.
- Medical students and educators who require reliable oncology resources.
- Policy-makers and healthcare organizations interested in cancer prevention and treatment advancements.
SEO Benefits and Online Presence
The journal's website and published articles rank highly on search engines due to their authoritative content and high citation rates. SEO strategies that contribute to its visibility include:- Keyword Optimization: Articles feature relevant oncology-related keywords, enhancing discoverability.
- High-Quality Backlinks: Cited by reputable medical and scientific publications, increasing domain authority.
- Regular Content Updates: Frequent publication of new reviews ensures fresh and engaging content.
- Engagement on Digital Platforms: Presence on research databases, social media, and academic forums boosts online interaction.
Recent Research Articles
Latest publications matched automatically by ISSN.
Liver resection improves survival in patients with locally advanced HCC
Peter Sidaway
2026-09-07 · DOI: 10.1038/s41571-026-01202-6Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology
William Jia, Ronghua Zhao, Howard L. Kaufman, Robert L. Martuza et al.
2026-09-03 · DOI: 10.1038/s41571-026-01198-zBelzutifan plus lenvatinib delays disease progression in advanced-stage RCC
Peter Sidaway
2026-08-27 · DOI: 10.1038/s41571-026-01200-8Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems
Monireh Sadat Seyyedsalehi, Paolo Boffetta
2026-08-26 · DOI: 10.1038/s41571-026-01199-yExploring the landscape of targetable alterations in patients with glioblastoma
Elisa Aquilanti, Mehdi Touat, Pim French, Antonio Iavarone et al.
2026-08-19 · DOI: 10.1038/s41571-026-01190-7Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma
Fen Saj, Lipika Goyal
2026-08-12 · DOI: 10.1038/s41571-026-01194-3How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease
Daniel E. Spratt
2026-08-11 · DOI: 10.1038/s41571-026-01193-4The proteome comes of age, but precision oncology needs functional maps
Emanuel Petricoin, Thomas Conrads, Lance Liotta
2026-08-10 · DOI: 10.1038/s41571-026-01196-1AI-based augmentation of oncology clinical trials
Andrea Villa, Ashley L. Eadie, David Synnott, Rebecca Romanò et al.
2026-08-07 · DOI: 10.1038/s41571-026-01189-0HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL
David Killock
2026-08-07 · DOI: 10.1038/s41571-026-01197-0Benefit from perioperative enfortumab vedotin–pembrolizumab in cisplatin-eligible MIBC
Diana Romero
2026-08-04 · DOI: 10.1038/s41571-026-01195-2More options, more questions in the management of early relapsed and/or refractory multiple myeloma
Carlyn Rose Tan, Sham Mailankody
2026-07-31 · DOI: 10.1038/s41571-026-01191-6Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
Solange Peters, Petros Grivas, Christophe Massard, Sara M. Tolaney et al.
2026-07-30 · DOI: 10.1038/s41571-026-01188-1De-escalation trials in multiple myeloma: past, present and future
Hira Mian, Luciano J. Costa, Mohamad Mohty, Alfred Garfall et al.
2026-07-29 · DOI: 10.1038/s41571-026-01186-3Electronic cigarettes, smoking and lung cancer risk: some evidence about the continuum of harm
Peter G. Shields
2026-07-28 · DOI: 10.1038/s41571-026-01192-5Towards liquid biopsy-based analysis of antitumour immunity
Klaus Pantel, Doryan Masmoudi, Catherine Alix-Panabières
2026-07-24 · DOI: 10.1038/s41571-026-01181-8Does OptiTROP-Lung05 open a new frontier for first-line ADC–ICI combinations in NSCLC?
Myung-Ju Ahn
2026-07-20 · DOI: 10.1038/s41571-026-01183-6Crossover does not confound, it informs: 177lutetium-PSMA-617 as an example
Martin W. Schoen, Tito Fojo, Johann de Bono
2026-09 · DOI: 10.1038/s41571-026-01182-7Second-line 177Lu-edotreotide shows promise in GEP NETs
Diana Romero
2026-07-16 · DOI: 10.1038/s41571-026-01187-2The future of ciltacabtagene autoleucel in multiple myeloma has just begun
Maximilian Merz, Nico Gagelmann
2026-09 · DOI: 10.1038/s41571-026-01184-5Reviews
Community Reviews
No approved community reviews yet. Be the first to contribute a verified experience.
Write a ReviewVersion History
Profile last updated
April 10, 2025 at 7:35 am
Profile published
March 13, 2025